Loading…
Loading…
Concurrent Investment Advisors LLC raised its stake in GRAIL, Inc. (NASDAQ: GRAL) by 65.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 30,253 shares of the company's stock after acquiring an additional 12,002 shares during the quarter. Concurrent Investment
The transaction was valued at approximately $672,000. The shares traded represented 3% of the direct equity stake held by the CFO prior to the filing.
FDA approval is crucial for Galleri's adoption by insurers. The company received some good news from the FDA, and a pivotal meeting is coming up for Grail's Galleri test.
SUNNYVALE, Calif., Sept. 3, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 55,867 shares of GRAIL's common stock to 59 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL.
MENLO PARK, Calif., Aug. 31, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Monday, Sep. 14 at 11:30 a.m.
GRAIL NASDAQ: GRAL Chief Financial Officer Aaron Freidin said the company's Galleri multi-cancer early detection test recorded strong first-half growth as it expanded distribution through digital health platforms, employers and physician offices.
Bank of America Corp DE raised its holdings in shares of GRAIL, Inc. (NASDAQ: GRAL) by 29.0% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 914,114 shares of the company's stock after purchasing an additional 205,611 shares
GRAIL faces a binary FDA approval event for Galleri, with significant stock movement expected based on the outcome. Despite disappointing NHS-Galleri trial results, I believe the true value of the test would have been apparent with a longer monitoring period. While GRAL has a solid cash position, commercialization delays could see the company having to raise a large amount of capital on unfavorable terms.